My Health Partner Logo

About My Health Partner

Our mission

Our mission

Empower the patient in the daily management of his/her chronic disease, by providing information about the pathology and offering daily activities and recipes to reduce risks of cardiovascular events.

Our essence

Our essence

Servier puts the patient at the core of its activity. Creating innovative tools to help patients enhance their lives is our key challenge.

Our promise

Our promise

Provide personalized, certified, and updated content for patients with multiple cardiovascular risks to have a healthier life.

Why myhealthpartner.ie ?

An estimated 17.9 million people died from CVDs in 2016, representing 31% of all global deaths.1 Because most CVDs can be prevented, people with cardiovascular disease or who are high cardiovascular risk (due to the presence of one or more risk factors such as hypertension, diabetes…) need reliable and certified content that is dynamic, with personalized advice according to their diseases and interests.

myhealthpartner.ie will select and suggest specific content for you, based on its relevance to your own conditions, via specific questions during the first visit to the platform (age, lifestyle, conditions, etc). No personal data is recorded, and some of the content of the platform will be automatically customized according to your answers.

About Servier

Founded to serve health, Servier is a global group governed by a Foundation that aspires to have a meaningful social impact, both for patients and for a sustainable world. With its unique governance model, it can fully serve its vocation with a long-term vision: being committed to therapeutic progress to serve patient needs. As a world leader in cardiology, Servier's ambition is to become a renowned, focused and innovative player in oncology by targeting hard-to-treat cancers. Neuroscience and immuno-inflammatory diseases are the future growth driver. In these areas, Servier is focused on a limited number of diseases in which accurate patient profiling makes it possible to offer a targeted therapeutic response through precision medicine. To promote access to quality care for all at a lower cost, the Group also offers a range of quality generic drugs covering most pathologies. In all these areas, the Group includes the patient voice at each stage of the life cycle of a medicine.

To promote access to quality care for all at a lower cost, the Group also offers a range of quality generic drugs covering most pathologies. In all these areas, the Group includes the patient voice at each stage of the life cycle of a medicine.